Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acebilustat in outpatient COVID-19
NCT04662060Phase 2Completed
- Sponsor
- Stanford University
- Start
- Apr 2021
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Acebilustat with Matching Placebo (2 arms). Primary endpoint: Time to Sustained Resolution of COVID-19 Symptoms at 28 days. Started Apr 2021; status: completed.
02
Drugs
acebilustat
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04662060.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04662060.